Anteris Technologies has closed a $320 million capital raise, combining a $230 million public offering and a strategic private placement with Medtronic, to advance its DurAVR heart valve clinical trials and manufacturing growth.
- Raised approximately US$320 million through public offering and Medtronic private placement
- 40 million shares sold publicly at US$5.75 each, including full underwriter option exercise
- Medtronic acquired 15.65 million shares in a private placement at the same price
- Funds earmarked for DurAVR pivotal trial, manufacturing expansion, and R&D
- Clinical trial enrolment underway with first implants in Denmark during late 2025
Capital Raise Overview
Anteris Technologies Global Corp., a company focused on innovative structural heart medical devices, has successfully closed a significant equity raise totaling approximately US$320 million. This capital infusion comprises a US$230 million public offering of 40 million common shares priced at US$5.75 each, including the full exercise of the underwriters’ option, alongside a private placement of over 15.6 million shares to medical device giant Medtronic at the same price.
Strategic Partnership with Medtronic
The private placement to Medtronic, executed through its wholly owned subsidiary, signals a strategic alignment between the two companies. Medtronic’s investment not only provides Anteris with substantial capital but also potentially opens doors for collaboration and validation within the competitive structural heart market. The partnership could accelerate the commercialisation pathway for Anteris’ lead product, the DurAVR Transcatheter Heart Valve (THV).
Funding Clinical and Manufacturing Growth
Proceeds from the capital raise will primarily support the ongoing global pivotal PARADIGM Trial for the DurAVR THV, which targets patients suffering from severe aortic stenosis; a serious narrowing of the aortic valve. The trial has already commenced with initial patient implants in Denmark during the fourth quarter of 2025. Additionally, Anteris plans to expand its manufacturing capabilities to meet anticipated demand and invest in research and development for its subsidiary, v2vmedtech, inc., ensuring continued innovation in the heart device space.
Technology and Market Potential
The DurAVR THV stands out as the first biomimetic valve designed to replicate the natural function of a healthy human aortic valve. Its unique construction uses Anteris’ patented ADAPT anti-calcification tissue technology, which has a decade-long clinical track record and has been used in over 55,000 patients worldwide. This positions Anteris well in a market hungry for durable, effective transcatheter heart valve solutions.
Looking Ahead
With the capital raise now complete, Anteris is well-funded to advance its clinical programs and scale manufacturing. The involvement of established financial institutions like Barclays, Wells Fargo Securities, and Cantor Fitzgerald, alongside advisory support from Barrenjoey Markets, underscores the market’s confidence in Anteris’ growth trajectory. Investors will be watching closely as the PARADIGM Trial progresses and as the company moves toward potential regulatory approvals and commercial launch.
Bottom Line?
Anteris’ substantial capital raise and Medtronic partnership set the stage for critical clinical milestones and potential market disruption in heart valve therapy.
Questions in the middle?
- How will Medtronic’s involvement influence Anteris’ commercial strategy and product rollout?
- What are the timelines and key endpoints for the PARADIGM pivotal trial?
- How might this equity raise impact existing shareholders in terms of dilution and future valuation?